Filters
Also try searching for:
BEQ*
on 22 Nov 2024
G2S Tobeq Inc.
2251205 · 12 Apr 2023
006
Class 006
Metal Products
Tool boxes of metal
008
Class 008
Hand Tool Products
Hand tools; hand-operated lifting jacks; manually operated jacks
Tool boxes of metal,Hand tools; hand-operated lifting jacks; manually ...
on 25 Apr 2024
GLOBAL BLOOD THERAPEUTICS INC.
2210021 · 15 Aug 2022
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for the treatment of vaso-occlusive crisis; pharmaceutical preparations for the treatment of hematological disorders such as sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions.
Pharmaceutical preparations for the treatment of vaso-occlusive crisis...
on 05 Feb 2024
CELGENE CORPORATION
2064591 · 18 Nov 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
Pharmaceutical preparations for human use for the treatment and preven...
on 11 Jan 2024
CELGENE CORPORATION
2064554 · 17 Nov 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use.
Pharmaceutical preparations for human use.
on 11 Jan 2024
CELGENE CORPORATION
2064552 · 17 Nov 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use.
Pharmaceutical preparations for human use.
on 05 Feb 2024
CELGENE CORPORATION
2064553 · 17 Nov 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
Pharmaceutical preparations for human use for the treatment and preven...
on 11 Jan 2024
CELGENE CORPORATION
2064557 · 17 Nov 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use.
Pharmaceutical preparations for human use.
on 12 Feb 2024
CELGENE CORPORATION
2058325 · 19 Oct 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
Pharmaceutical preparations for human use for the treatment and preven...
on 29 Dec 2023
CELGENE CORPORATION
2058236 · 16 Oct 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use
Pharmaceutical preparations for human use
on 24 Nov 2023
CELGENE CORPORATION
2049676 · 03 Sep 2020
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as antiinfectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies.
Pharmaceutical preparations for human use for the treatment and preven...
Country
CA
Status
All
Registered
Pending
Abandoned
Other
Owners
Celgene corporation (8)
Merck kgaa (2)
Franchises bo-beq inc.. (1)
G2s tobeq inc.. (1)
Global blood therapeutics inc.. (1)
Mbeq llc (1)
Plethora solutions holdings plc (1)
Categories
Class 5 (11)
Class 6 (1)
Class 8 (1)
Class 41 (1)
Class 43 (1)
Class 44 (1)
Correspondents
Gowling wlg (canada) llp (8)
Smart & biggar ip agency co. (2)
Borden ladner gervais llp (1)
Canyon ip inc.. (1)
Smart & biggar lp (1)
Image Search
Drag and drop or upload to search any image
Page 1 of 2